Teplizumab approval for type 1 diabetes in the USA

Lancet Diabetes Endocrinol. 2023 Feb;11(2):77-78. doi: 10.1016/S2213-8587(22)00391-6. Epub 2023 Jan 6.

Authors

Olga Kordonouri¹, Felix Reschke¹, Thomas Danne²

Affiliations

¹ Diabetes Center, Children's Hospital "Auf Der Bult", D-30173 Hannover, Germany.
² Diabetes Center, Children's Hospital "Auf Der Bult", D-30173 Hannover, Germany. Electronic address: [email protected].

PMID: 36623521
DOI: 10.1016/S2213-8587(22)00391-6

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Diabetes Mellitus, Type 1* / drug therapy
Humans
Hypoglycemic Agents

Substances

Antibodies, Monoclonal, Humanized
Hypoglycemic Agents
teplizumab